Oncolys BioPharma Inc. (TYO:4588)

Japan · Delayed Price · Currency is JPY

2,629.00

-84.00 (-3.10%)

Aug 6, 2026, 10:45 AM JST

Oncolys BioPharma Financials Overview

Financials in millions JPY. Fiscal year is January - December.

Millions JPY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	28.55	31.38	63.04	976.18	642.49	314.18
Revenue Growth	-9.04%	-50.21%	-93.54%	51.94%	104.50%	-75.90%
Gross Profit	28.55	31.38	30.61	338.49	198.8	236.11
Operating Income	-2,031	-1,688	-1,931	-1,222	-1,523	-1,689
Net Income	-2,055	-1,685	-1,939	-1,149	-1,615	-2,095
Earnings Per Share	-82.55	-77.17	-108.92	-66.31	-95.50	-145.58
EPS Growth	-	-	-	-	-	-

Revenue by Geography

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
United States of America	31.38	28.04	25.79	35.93	84.44
Japan	-	35	950.39	318.91	138.91
Total	31.38	63.04	976.18	642.49	314.18

Cash & Debt

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Investments	1,352	2,411	1,533	1,711	3,455	2,068
Total Debt	339.24	324.64	315.17	393.66	503.47	525.08
Net Cash (Debt)	1,013	2,086	1,218	1,318	2,951	1,543
Net Cash Growth	-22.84%	71.34%	-7.58%	-55.35%	91.29%	-45.18%
Net Cash Per Share	40.68	95.57	68.42	76.04	174.47	107.20

Cash Flow & CapEx

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Cash Flow	-	-2,020	-1,337	-1,717	-1,742	-1,465
Capital Expenditures	-	-3.52	-5.69	-1.36	-1.44	-2.7
Free Cash Flow	-	-2,024	-1,343	-1,718	-1,743	-1,468
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Gross Margin	100.00%	100.00%	48.55%	34.67%	30.94%	75.15%
Operating Margin	-7116.10%	-5377.29%	-3062.62%	-125.21%	-237.06%	-537.45%
Pretax Margin	-7187.43%	-5356.28%	-3070.50%	-117.40%	-250.85%	-665.66%
Profit Margin	-7199.36%	-5368.27%	-3075.14%	-117.70%	-251.43%	-666.85%
FCF Margin	-	-6447.89%	-2129.84%	-176.04%	-271.33%	-467.22%

Valuation

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug '26 Aug 6, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
PS Ratio	2784.85	410.43	172.56	9.35	14.27	69.93